



Bayer AG
Communications and
Public Affairs
51368 Leverkusen
Germany
Tel. +49 214 30-1
media.bayer.com

News Release

First Anniversary of Bayer's Transparency Initiative

Bayer committed to transparency: Posts more than 300 glyphosate safety study summaries online

Monheim, December 7, 2018 – Today, Bayer marks the first anniversary of its Transparency Initiative, designed to enhance trust in the science behind crop protection products. As another important milestone in the company's efforts to make science more accessible, Bayer is making available more than 300 study summaries on the safety of glyphosate on its dedicated [transparency platform](#).

"Trust in the integrity of crop protection science is core to us and our business," said Liam Condon, member of the Board of Management of Bayer AG and President of the Crop Science Division. "The public is interested in knowing more about how their food is grown and what products are involved in the production of food. Crop protection products are used by farmers to protect harvests from disease, pests and weeds. As one of the leaders in agriculture, we have been working diligently to make studies on crop protection substances available beyond regulatory requirements. We want to explain the benefits that science and innovation can deliver in agriculture while championing what's important to people: safe, healthy and affordable food that is produced in an environmentally sustainable manner. Improving access to the science behind our products is a key part of our Transparency Initiative."

Similar to the other substances included within its Transparency Initiative, Bayer is focusing on safety studies submitted under the European Union (EU) substance authorization process for plant protection products. On the website you can find the study summaries for studies on residues and metabolism (18), environmental fate (32), toxicology (180), and ecotoxicology (88) on the active substance as well as representative formulations. More information can be found on the [FAQ page](#).

Access to the much more extensive underlying safety study reports will be enabled in 2019; this will include those owned by Bayer and submitted for the review that led to the European substance authorization renewal decision in December 2017.

The science behind the safety of glyphosate

Over the last 40 years, glyphosate and glyphosate-based formulations have been extensively evaluated for human health and safety. Most of this scientific research on glyphosate was conducted by independent researchers.

For additional research conducted on glyphosate, visit the European Food Safety Authority ([EFSA](#)), the U.S. Environmental Protection ([EPA](#)) and the [glyphosate task force](#). Background information on glyphosate and its history as a safe and efficient weed control tool for farmers around the world is also available [here](#).

About Bayer

Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2017, the Group employed around 99,800 people and had sales of EUR 35.0 billion. Capital expenditures amounted to EUR 2.4 billion, R&D expenses to EUR 4.5 billion. For more information, go to www.bayer.com.

Contact:

Utz Klages, phone +49 2173 38-3125

Email: utz.klages@bayer.com

Find more information at www.bayer.com.

kgs (2018-0266E)

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.